STAT+: As Ginkgo stock sinks, CEO Jason Kelly tries to win over drugmakers in San Francisco
SAN FRANCISCO — Ginkgo Bioworks CEO Jason Kelly is here trying to convince the world’s…
Category: STAT+
STAT+: With the FTC’s more expansive approach to antitrust, PBMs are in the crosshairs
WASHINGTON — The Democrats leading the Federal Trade Commission are hoping to expand the agency’s…
STAT+: California is the latest state to sue drugmakers and PBMs over insulin pricing
The California attorney general has filed a lawsuit accusing several drugmakers and pharmacy benefit managers…
.jpg)
STAT+: Regeneron executive George Yancopoulos admits some regret, but ‘I don’t apologize’
SAN FRANCISCO — George Yancopoulos isn’t apologizing. The president and chief scientist of Regeneron was…
STAT+: Pharmalittle: HHS readying details for Medicare drug-price negotiations; doctors urge FDA to hold expert meeting before approving Alzheimer’s drug
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: Medicare paves the way for CAR-T in doctors offices
WASHINGTON — Medicare officials have taken a step toward making a cutting-edge cancer treatment called…
STAT+: Drastic changes should bring profitability, startup health insurers say
Startup insurers Oscar Health, Bright Health, and Clover Health have hemorrhaged money since going public…
STAT+: Physicians group urges FDA to convene expert panel before finally approving an Alzheimer’s drug
A physicians group is urging the Food and Drug Administration to hold an expert panel…
STAT+: Top Verily executives depart amid leadership shakeup and layoffs
Verily, a health technology company spun out of tech giant Alphabet, announced Wednesday that it…
.jpg)
STAT+: HHS will seek more input on its new Medicare drug price negotiations
WASHINGTON — The Department of Health and Human Services is gearing up to start releasing…
STAT+: Upstart Element ratchets up race for cheaper DNA sequencing with a $200 genome
SAN FRANCISCO — Decoding the billions of chemical letters that help shape who we are…
STAT+: Pharmalittle: Pfizer will not license generic Covid-19 pill in China; BioMarin signs outcomes-based deal in Germany for gene therapy
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Lawmakers again urge the Biden administration to use federal law to widen access to a cancer drug
For the third time in less than a year, a group of lawmakers is urging…
Will America’s public health reckoning ever come?
WASHINGTON — After 9/11, Congress created an entirely new government agency to address the threat of…
STAT+: Insurers hint at suing Biden administration over plans for Medicare Advantage audits
Big health insurers who spoke at the J.P. Morgan Healthcare Conference are gearing up to…
STAT+: Still hoping for looser FDA rules, Regeneron says it will test durable antibody for Covid
SAN FRANCISCO — For months, drugmakers have been pleading with regulators to lower the bar…
STAT+: HHS will decide how to resolve $1 billion in payments for 340B hospitals
WASHINGTON — The Department of Health and Human Services will get to decide how to…
STAT+: FDA scolds Sun Pharmaceutical for serious quality control problems at a key plant in India
Sun Pharmaceutical, one of the world’s largest generic drugmakers, was scolded by the U.S. Food…
STAT+: Hospitals say peak labor costs are behind them
SAN FRANCISCO — Rising labor costs has been the main financial concern for hospitals over…
An FDA pathway to clear medical devices is putting patients at risk, research suggests
The Food and Drug Administration’s approach to evaluating some new medical devices might actually increase…
STAT+: Pharmalittle: FDA increasingly pauses trials of experimental meds; FDA commish isn’t surprised by congressional report on Alzheimer’s drug
Rise and shine, another busy day is on the way. We can tell if only…
STAT+: People hate drug ads on TV. Here’s what they complain about most
In the United States, pharmaceutical advertising seems inescapable. Since the first prescription drug ad ran…
STAT+: Medicare Advantage-focused Oak Street, Agilon Health chart out growth at J.P Morgan
Senior-focused primary care providers Oak Street Health and Agilon Health used their stage time at…
STAT+: New Biogen CEO: New drug launches, more cost cuts, but no ‘radical left turns’ needed
SAN FRANCISCO — In some of his first extended comments since taking over as Biogen’s…
STAT+: Rep. Jason Smith and the other Republicans leading health policy in the House
Rep. Jason Smith of Missouri will helm the powerful House Ways & Means Committee this…
STAT+: Moderna plans to follow in Pfizer’s footsteps, charge up to $130 for Covid-19 vaccine in U.S.
Moderna disclosed Monday that it plans to price its Covid-19 vaccine at anywhere from $110…
STAT+: Study finds heavier reliance on nurse practitioners, physician assistants after private equity takeovers
A new study suggests physician practices acquired by private equity rely more heavily on advanced…
STAT+: Novavax replaces CEO, citing need for “fresh perspective”
The vaccine maker Novavax, which has faced several years of dramatic ups and downs around…
STAT+: A flurry of pharma acquisitions kick off JPM week after a slow year for deals
SAN FRANCISCO — Within the first hours of the J.P. Morgan Healthcare Conference, four life…
STAT+: Pharmalittle: Pediatricians recommend obesity drugs for children; as JPM starts, industry execs have a gloomy financing outlook
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Arrowhead RNA treatment improves liver scarring in patients, but so does a placebo, clouding study results
An experimental RNA treatment reduced liver scarring in half of patients with an inherited disease…
STAT+: Mental health data complicate the question of whether telehealth drives up costs
The surge in telehealth during the pandemic promised to shed light on a crucial question:…
STAT+: Day One says drug shrinks tumors in common pediatric brain cancer, setting up potential approval
Day One Biopharmaceuticals said Sunday that a targeted therapy shrank tumors by at least 50%…
STAT+: The health care providers and insurers we’re watching at JPM23 — and why
Hospitals, health insurers, and other provider-related companies are returning in person to the J.P. Morgan…
STAT+: Money troubles and M&A: What’s on biotech insiders’ minds ahead of a not-so-celebratory JPM week
SAN FRANCISCO — What should be a triumphant return to the global biotech industry’s biggest…
STAT+: The FDA has approved a new Alzheimer’s drug, but wide access may depend on CMS easing restrictions
Now that the U.S. Food and Drug Administration has granted accelerated approval to the widely…
STAT+: Pharmalittle: Pfizer scaling back early-stage research into rare diseases; BioNTech and U.K. partner on cancer trials
And so, another working week will soon draw to a close. Not a moment too…
Opinion: STAT+: Continuous manufacturing can help pharma companies save time, money, and more
The pharmaceutical industry has been slow to adopt a business practice that is faster, safer,…
STAT+: Fate Therapeutics plans mass layoffs, after early end to cell therapy deal with Janssen
SAN DIEGO — Fate Therapeutics, a biotech upstart with big ambitions to use cell-based therapies…
STAT+: Pharma’s ambitious antibiotic venture fund makes another investment
For only the second time since launching nearly two years ago, the AMR Action Fund…
STAT+: Pharmalittle: New report gives glimpse into safety of an Alzheimer’s drug; Walgreens looks to dispense an abortion pill
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Biogen shakes up R&D chief role, makes Singhal permanent replacement
More than a year after Al Sandrock was pushed out as Biogen’s R&D chief, the…
STAT+: 3 drug pricing issues to watch in 2023
WASHINGTON — The legislative saga on drug pricing is mostly over for now, but drug…
STAT+: ‘Stuck in a rut’: As debate flares over access to medicines, the future of voluntary licensing is up in the air
ANNECY, FRANCE — At first blush, the deal was hailed as a breakthrough. Last fall,…
STAT+: As FDA considers new Alzheimer’s drug, a case study details safety concerns
Investigators on Wednesday released the first detailed case report about a patient who died after…
STAT+: Pharmalittle: FDA rule change allows pharmacies to offer abortion pills; Medicare could have saved billions if inflationary rebate law existed
Top of the morning to you, and a fine one it is. Balmy breezes and…
STAT+: Roivant-Pfizer inflammatory bowel drug hits high expectations in mid-stage study
An experimental inflammatory bowel disease medicine that serves as the basis for a partnership between…
STAT+: The health tech tracker for 2023’s first quarter: 12 industry events to watch
Continuing economic uncertainty and the threat of a recession are casting a pall over health…
STAT+: Medicare would have saved $3.7 billion on Part B drugs if inflationary rebates were around in a recent three-year period
If rebates had been required for price hikes on most of the nearly 100 medicines…
STAT+: Pharmalittle: Pharma plans to raise U.S. drug prices in January; U.S. sues AmerisourceBergen over opioid crisis
Good morning, everyone, and welcome to a new year. We hope the holiday respite was…